Your browser doesn't support javascript.
loading
Tissue-Agnostic Cancer Therapy Approvals.
Gouda, Mohamed A; Subbiah, Vivek.
Afiliação
  • Gouda MA; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Unit 455, Houston, TX, USA.
  • Subbiah V; Early-Phase Drug Development, Sarah Cannon Research Institute, 335 24th Avenue North Suite 300, Nashville, TN 37203, USA. Electronic address: Vivek.Subbiah@scri.com.
Surg Oncol Clin N Am ; 33(2): 243-264, 2024 Apr.
Article em En | MEDLINE | ID: mdl-38401908
ABSTRACT
Tumor-agnostic, or histology-agnostic, cancer therapy marks a groundbreaking evolution in the realm of precision oncology. In stark contrast to conventional cancer treatments that categorize malignancies based on their tissue of origin (eg, breast, lung, renal cell, etc), tumor-agnostic therapies transcend histologic boundaries, honing in on the genetic and molecular attributes of tumors, regardless of their location. This article offers a comprehensive review of the current landscape of tissue-agnostic cancer therapies and provides clinical insights to empower surgical oncologists with a deeper understanding of these innovative therapeutic approaches.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias Idioma: En Ano de publicação: 2024 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias Idioma: En Ano de publicação: 2024 Tipo de documento: Article